Review
Biochemistry & Molecular Biology
Ahmed Abu-Zaid, Duha Magzoub, Mohammad Abdulrahman Aldehami, Abdulrahman Adel Behiry, Akshaya Srikanth Bhagavathula, Raouf Hajji
Summary: Iron treatment is associated with a significant decrease in FGF23 levels in CKD patients, with oral iron therapy being more effective than intravenous iron therapy.
BIOLOGICAL TRACE ELEMENT RESEARCH
(2021)
Article
Cell Biology
Chun-Hsing Liao, Hsu-Feng Lu, Hsin-Hui Huang, Yu Chen, Li-Hua Li, Yi-Tsung Lin, Tsuey-Ching Yang
Summary: This study focused on elucidating the ferric citrate acquisition system of S. maltophilia, revealing the involvement of FciTABC and FeoABI systems in ferric citrate acquisition.
JOURNAL OF BIOMEDICAL SCIENCE
(2022)
Article
Urology & Nephrology
Mark R. Hanudel, Brian Czaya, Shirley Wong, Maxime Rappaport, Shweta Namjoshi, Kristine Chua, Grace Jung, Victoria Gabayan, Bo Qiao, Elizabeta Nemeth, Tomas Ganz
Summary: This study demonstrates the efficacy of ferric citrate in high hepcidin models and shows that enteral ferric citrate absorption is dependent on conventional enterocyte iron transport by ferroportin, with minimal paracellular absorption occurring in these models.
KIDNEY INTERNATIONAL
(2022)
Article
Urology & Nephrology
Jose E. Navarrete, Oyintayo Ajiboye, Janice Lea
Summary: The use of ferric citrate in patients receiving peritoneal dialysis (PD) leads to significant iron accumulation, as indicated by increased ferritin levels.
PERITONEAL DIALYSIS INTERNATIONAL
(2023)
Article
Urology & Nephrology
Jose Portoles-Perez, Beatriz Dura-Gurpide, Jose Luis Merino-Rivas, Leyre Martin-Rodriguez, Covadonga Hevia-Ojanguren, Victor Burguera-Vion, Claudia Yuste-Lozano, Luisa Sanchez-Garcia, Jose Ramon Rodriguez-Palomares, Vicente Paraiso
Summary: The study aimed to evaluate the efficacy and safety of intravenous ferric carboxymaltose (FCM) in patients undergoing peritoneal dialysis (PD). The findings showed that FCM treatment was effective, safe, and easy to administer during routine clinical visits for PD patients.
CLINICAL KIDNEY JOURNAL
(2021)
Article
Biochemistry & Molecular Biology
Peter W. Halcrow, Nirmal Kumar, Zahra Afghah, Jalyn P. Fischer, Nabab Khan, Xuesong Chen, Olimpia Meucci, Jonathan D. Geiger
Summary: Endolysosomes play a crucial role in iron metabolism and redox signaling. This study quantitatively measured the levels of ferrous iron (Fe2+) in endolysosomes and investigated its effects on endolysosome morphology, distribution and function. The findings suggest that the fluorescence dye FeRhoNox-1 is a useful probe for studying endolysosome Fe2+, and further research is needed to better understand the physiological and pathological significance of endolysosomes with different iron content.
JOURNAL OF NEUROCHEMISTRY
(2022)
Review
Biochemistry & Molecular Biology
Kuo-Hua Lee, Yang Ho, Der-Cherng Tarng
Summary: Anemia is a common issue in patients with chronic kidney disease, and novel iron replacement therapies have shown to be effective in reducing medical costs and improving anemia in these patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Agriculture, Multidisciplinary
Amelia Faradina, Yu-Tang Tung, Seu-Hwa Chen, Yu-Chi Liao, Meng-Jung Chou, I-Chun Teng, Wen-Ling Lin, Ching-Chiung Wang, Ming-Thau Sheu, Po-Yu Chou, Chun-Kuang Shih, Anatoly V. Skalny, Alexey A. Tinkov, Jung-Su Chang
Summary: This study found that djulis hull (DH) has positive effects on iron metabolism in obese rats, increasing serum and hepatic iron levels while decreasing appetite hormones, body weight, hepcidin, and liver inflammation. DH can downregulate hepatic hepcidin through the IL-6-JAK-STAT3 pathway and enhance ferroportin via the Keap1-Nrf2 and PHD2-HIF-2 alpha pathways.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
(2023)
Article
Urology & Nephrology
Marisa Roldao, Rachele Escoli, Hernani Goncalves, Ana Vila Lobos
Summary: Studies on patients with non-dialysis chronic kidney disease have shown that intravenous iron therapy can effectively improve serum iron levels and anemia, with higher doses having a positive impact on renal function.
INTERNATIONAL UROLOGY AND NEPHROLOGY
(2023)
Article
Transplantation
Annabel Biruete, Corinne E. Metzger, Neal X. Chen, Elizabeth A. Swallow, Curtis Vrabec, Erica L. Clinkenbeard, Alexander J. Stacy, Shruthi Srinivasan, Kalisha O'Neill, Keith G. Avin, Matthew R. Allen, Sharon M. Moe
Summary: This study compared the effects of ferric citrate (FC) and intravenous iron sucrose in rats with moderate chronic kidney disease (CKD). The results showed that FC treatment improved phosphorus homeostasis, some iron-related parameters, and the production and cleavage of FGF23. However, neither iron treatment had a significant effect on cardiovascular calcification and bone.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2022)
Article
Urology & Nephrology
Pablo E. Pergola, Diogo Belo, Paul Crawford, Moustafa Moustafa, Wenli Luo, Alexander Goldfarb-Rumyantzev, Youssef M. K. Farag
Summary: This study investigated the long-term efficacy and safety of different FC dosing regimens for treating anemia in nondialysis-dependent CKD patients. Both twice daily and three times daily FC treatments were found to be safe and effective in improving hemoglobin levels in this population, suggesting potential dosing flexibility with FC.
AMERICAN JOURNAL OF NEPHROLOGY
(2021)
Article
Soil Science
Chaoqun Wang, Lukas Thielemann, Michaela A. Dippold, Georg Guggenberger, Yakov Kuzyakov, Callum C. Banfield, Tida Ge, Stephanie Guenther, Maxim Dorodnikov
Summary: Changes in rice root morphology reflect the decrease in phosphorus (P) deficiency after the dissolution of ferric iron (Fe(III))-bound phosphate (Fe-P) in low-redox paddy soils. A new in-situ 32P phosphor-imaging approach was developed to estimate P uptake by rice roots released from Fe-P dissolution. Direct root access to Fe-P increased rice crown roots elongation, branching, and P accessibility under P deficiency.
SOIL BIOLOGY & BIOCHEMISTRY
(2023)
Article
Urology & Nephrology
Keitaro Yokoyama, Teruo Hashimoto, Yuri Okuda, Yu Matsumoto, Kyoko Ito, Ryoichi Yamada, Hiroyuki Susai, Noriaki Nishino
Summary: This post-marketing surveillance study in Japan involving 2723 CKD patients showed that most patients experienced an increase in iron-related parameters after starting FC treatment, which stabilized after week 36, while serum phosphorus levels immediately decreased and remained lowered for 104 weeks. The study concluded that there were no new safety concerns with long-term FC treatment and that it effectively controlled serum phosphorus levels.
CLINICAL AND EXPERIMENTAL NEPHROLOGY
(2022)
Article
Geriatrics & Gerontology
Tilmann Kramer, Max Wissmueller, Kristiana Natsina, Felix Gerhardt, Henrik ten Freyhaus, Daniel Dumitrescu, Thomas Viethen, Martin Hellmich, Stephan Baldus, Stephan Rosenkranz
Summary: This study investigated the long-term effects of intravenous iron supplementation in patients with pulmonary arterial hypertension and iron deficiency. The results showed immediate and sustained improvement in iron status, as well as positive clinical outcomes such as increased exercise capacity, reduced hospitalizations, and improved functional class over 18 months.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE
(2021)
Article
Transplantation
Marcelo Barreto Lopes, Angelo Karaboyas, Junhui Zhao, David W. Johnson, Talerngsak Kanjanabuch, Martin Wilkie, Kosaku Nitta, Hideki Kawanishi, Jeffrey Perl, Ronald L. Pisoni
Summary: This study investigates the association between serum phosphorus levels and adverse outcomes in peritoneal dialysis (PD) patients. It finds that higher serum phosphorus levels are associated with increased morbidity and mortality, highlighting the need for improved treatment strategies in this population. The study suggests that serial serum phosphorus measurements should be considered when assessing patients' risks of adverse outcomes.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2023)
Article
Oncology
Emma Copland, Dexter Canoy, Milad Nazarzadeh, Zeinab Bidel, Rema Ramakrishnan, Mark Woodward, John Chalmers, Koon K. Teo, Carl J. Pepine, Barry R. Davis, Sverre Kjeldsen, Johan Sundstrom, Kazem Rahimi
Summary: This study found no consistent evidence linking antihypertensive medication use to cancer risk, providing reassurance to clinical practice. However, evidence for some comparisons was insufficient to entirely rule out excess risk, particularly for calcium channel blockers.
Article
Medicine, General & Internal
Cora E. Lewis, Lawrence J. Fine, Srinivasan Beddhu, Alfred K. Cheung, William C. Cushman, Jeffrey A. Cutler, Gregory W. Evans, Karen C. Johnson, Dalane W. Kitzman, Suzanne Oparil, Mahboob Rahman, David M. Reboussin, Michael V. Rocco, Kaycee M. Sink, Joni K. Snyder, Paul K. Whelton, Jeff D. Williamson, Jackson T. Wright, Walter T. Ambrosius
Summary: Among patients at increased cardiovascular risk, targeting a systolic blood pressure of less than 120 mm Hg resulted in lower rates of major adverse cardiovascular events and all-cause mortality compared to targeting a systolic blood pressure of less than 140 mm Hg, both during the trial and post-trial follow-up. However, some adverse events were more frequent in the intensive-treatment group.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Thomas A. Zelniker, Itamar Raz, Ofri Mosenzon, Jamie P. Dwyer, Hiddo H. J. L. Heerspink, Avivit Cahn, Erica L. Goodrich, Kyungah Im, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P. H. Wilding, Ingrid Gause-Nilsson, Anna Maria Langkilde, Marc S. Sabatine, Stephen D. Wiviott
Summary: The study showed that the relative risk reduction for cardiovascular events with dapagliflozin is consistent across different eGFR and UACR groups, with the greatest absolute benefit observed among patients with both reduced eGFR and albuminuria.
Article
Urology & Nephrology
Manjula Kurella Tamura, Sarah Gaussoin, Nicholas M. Pajewski, Greg Zaharchuk, Barry Freedman, Stephen R. Rapp, Alexander P. Auchus, William E. Haley, Suzanne Oparil, Jessica Kendrick, Christianne L. Roumie, Srinivasan Beddhu, Alfred K. Cheung, Jeff D. Williamson, John A. Detre, Sudipto Dolui, R. Nick Bryan, Ilya M. Nasrallah
Summary: This study aimed to investigate the effects of intensive blood pressure control on cerebral perfusion and structure in individuals with and without chronic kidney disease (CKD). The findings suggest that intensive blood pressure treatment in adults with early kidney disease does not appear to have a detrimental effect on brain perfusion or structure.
AMERICAN JOURNAL OF KIDNEY DISEASES
(2022)
Article
Endocrinology & Metabolism
Ofri Mosenzon, Stephen D. Wiviott, Hiddo J. L. Heerspink, Jamie P. Dwyer, Avivit Cahn, Erica L. Goodrich, Aliza Rozenberg, Meir Schechter, Ilan Yanuv, Sabina A. Murphy, Thomas A. Zelniker, Ingrid A. M. Gause-Nilsson, Anna Maria Langkilde, Martin Fredriksson, Peter A. Johansson, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P. H. Wilding, Marc S. Sabatine, Itamar Raz
Summary: In the DECLARE-TIMI 58 trial, dapagliflozin showed a positive impact on urinary albumin-to-creatinine ratio and renal-specific outcomes, improving across baseline UACR categories; indicating a potential role for SGLT2i in the primary prevention of diabetic kidney disease.
Article
Cardiac & Cardiovascular Systems
Zachary L. Cox, Bonnie Ann Sarrell, Mary Katherine Cella, Brent Tucker, Juan P. Arroyo, Kausik Umanath, William Tidwell, Andrew Guide, Jeffrey M. Testani, Julia B. Lewis, Jamie P. Dwyer
Summary: This study investigated the safety and efficacy of multinephron segment diuretic therapy (MSDT), which combines four diuretic classes, in acute heart failure patients with diuretic resistance. The results showed that MSDT increased diuresis without affecting serum chemistries or kidney function. This study provides evidence for further exploration of MSDT in acute heart failure and diuretic resistance.
JOURNAL OF CARDIAC FAILURE
(2022)
Article
Urology & Nephrology
Hiddo J. L. Heerspink, David Cherney, Douwe Postmus, Bergur Stefansson, Glenn M. Chertow, Jamie P. Dwyer, Tom Greene, Mikhail Kosiborod, Anna Maria Langkilde, John J. McMurray, Ricardo Correa-Rotter, Peter Rossing, C. David Sjostrom, Robert D. Toto, David C. Wheeler
Summary: This analysis of DAPA-CKD found that dapagliflozin can reduce the risk of abrupt declines in kidney function in patients with CKD and substantial albuminuria.
KIDNEY INTERNATIONAL
(2022)
Article
Medicine, General & Internal
Kazem Rahimi, Zeinab Bidel, Milad Nazarzadeh, Emma Copland, Dexter Canoy, Malgorzata Wamil, Jeannette Majert, Richard J. McManus, John Chalmers, Barry R. Davis, Carl J. Pepine, Koon K. Teo
Summary: A meta-analysis of randomized controlled trials found that pharmacological blood pressure reduction can reduce the risk of cardiovascular events in the elderly, with no variation in relative risk reduction based on age and baseline blood pressure levels, and greater absolute risk reductions in older age groups.
Article
Cardiac & Cardiovascular Systems
Dexter Canoy, Emma Copland, Milad Nazarzadeh, Rema Ramakrishnan, Ana-Catarina Pinho-Gomes, Abdul Salam, Jamie P. Dwyer, Farshad Farzadfar, Johan Sundstrom, Mark Woodward, Barry R. Davis, Kazem Rahimi
Summary: This study conducted a meta-analysis of individual patient-level data from randomized clinical trials to investigate the long-term effects of antihypertensive drugs on blood pressure. The results showed that antihypertensive drugs were effective in lowering blood pressure, with maximal effect observed after 12 months and gradual attenuation over time. The findings suggest the need for appropriate treatment strategies to sustain long-term blood pressure reductions.
Article
Endocrinology & Metabolism
Milad Nazarzadeh, Zeinab Bidel, Dexter Canoy, Emma Copland, Derrick A. Bennett, Abbas Dehghan, George Davey Smith, Rury R. Holman, Mark Woodward, Ajay Gupta, Amanda I. Adler, Malgorzata Wamil, Naveed Sattar, William C. Cushman, Richard J. McManus, Koon Teo, Barry R. Davis, John Chalmers, Carl J. Pepine, Kazem Rahimi
Summary: This study aimed to investigate the effects of blood pressure-lowering treatment on the risk of major cardiovascular events in individuals with and without type 2 diabetes. The results showed that a 5 mm Hg reduction in systolic blood pressure decreased the risk of major cardiovascular events in both groups, but the relative treatment effect was weaker in participants with type 2 diabetes. However, there was no substantial difference in absolute risk reductions between people with and without type 2 diabetes.
LANCET DIABETES & ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Ofri Mosenzon, Itamar Raz, Stephen D. Wiviott, Meir Schechter, Erica L. Goodrich, Ilan Yanuv, Aliza Rozenberg, Sabina A. Murphy, Thomas A. Zelniker, Anna Maria Langkilde, Ingrid A. M. Gause-Nilsson, Martin Fredriksson, Peter A. Johansson, John P. H. Wilding, Darren K. McGuire, Deepak L. Bhatt, Lawrence A. Leiter, Avivit Cahn, Jamie P. Dwyer, Hiddo J. L. Heerspink, Marc S. Sabatine
Summary: Dapagliflozin mitigated kidney function decline in patients with T2D at high cardiovascular risk, including those with low KDIGO risk, suggesting a role of dapagliflozin in the early prevention of diabetic kidney disease.
Review
Cell Biology
Samuel N. Heyman, Itamar Raz, Jamie P. Dwyer, Roni Weinberg Sibony, Julia B. Lewis, Zaid Abassi
Summary: Albuminuria is a hallmark of diabetic nephropathy and its development is influenced by various factors. Controlling glomerular albumin leak is crucial for preventing progression of the disease. Early interventions and treatments should be initiated before the onset of microalbuminuria, and the inhibition of the renin-angiotensin axis or sodium-glucose co-transport can be beneficial.
Article
Medicine, Research & Experimental
Jamie P. Dwyer, Abiy Agiro, Pooja Desai, Yemisi Oluwatosin
Summary: This study aimed to evaluate the impact of adding SZC therapy on 3-month medical costs in patients who experienced hyperkalemia while receiving RAASi therapy. The results showed that in patients who continued RAASi therapy with SZC, hyperkalemia-related and all-cause medical costs were significantly reduced, demonstrating cost savings with maintaining RAASi therapy with SZC.
ADVANCES IN THERAPY
(2023)
Article
Health Care Sciences & Services
Abiy Agiro, Jamie P. Dwyer, Yemisi Oluwatosin, Pooja Desai
Summary: The purpose of this study was to evaluate the impact of long-term sodium zirconium cyclosilicate (SZC) therapy on medical costs in patients with hyperkalemia. The study demonstrated that long-term outpatient treatment with SZC was associated with significant cost savings compared to no SZC therapy in patients with hyperkalemia.
CLINICOECONOMICS AND OUTCOMES RESEARCH
(2023)
Article
Medicine, General & Internal
Kazem Rahimi
Summary: In this study, a reduction of 5 mm Hg in systolic blood pressure was found to reduce the risk of major cardiovascular events by about 10%, regardless of previous cardiovascular disease diagnosis. This suggests that pharmacological blood pressure lowering is effective for both primary and secondary prevention of major cardiovascular disease.